OncoSec Medical Inc. , a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, announced today that the company has submitted a protocol addendum to the FDA and institutional IRBs to evaluate an increased dose frequency for ImmunoPulse in an expansion of its ongoing Phase II melanoma trial.
from Google News, Yahoo! News, Wikinews, NY Times National News by search term http://ift.tt/1fsOdTP
via IFTTT
from Google News, Yahoo! News, Wikinews, NY Times National News by search term http://ift.tt/1fsOdTP
via IFTTT
No comments:
Post a Comment